Business- Page 102

All-Cash Acquisition Completed; Company Remains Debt-Free Oblivus Provides On-Demand GPU Cloud Computing for AI Training and Inference and Operates a Proprietary GPU Marketplace Company Plans to Scale Rapidly From Approximately $1.5 Million

New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment Updated data to be presented from first-in-human trial of LB2501, an investigational, off-the-shelf in vivo CAR-T

Technology business recognized for specialized talent sourcing and expanded consulting capabilities Facts at a Glance: Kelly Technology + Motion Recruitment, a specialty division of Kelly®, has been recognized by Everest Group for

Company Achieves Important Capital Markets Milestone Following Restoration of SEC Reporting Compliance SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) — Royale Energy, Inc. (OTCQB: ROYL) (“Royale” or the “Company”) today announced that

WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present

BERKELEY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU) today announced that vispa-cel and CB-011 clinical abstracts have been accepted for two oral presentations and one poster presentation

The Remitly Global Card is the world’s first card that allows its users to text money and send money within the U.S. and to 175 countries, across 5 billion bank, cash, and

West Palm Beach, Fla. and Calgary, Alberta, Nov. 04, 2026 (GLOBE NEWSWIRE) — FingerMotion, Inc. (Nasdaq: FNGR) (“FingerMotion” or the “Company”) today announced that Brooks Campus No. 1 Inc., its wholly owned

Advances progress towards planned uplisting to National Securities Exchange CAMARILLO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Qualstar Corp. (OTC: QBAK), a custom designer and one-stop provider of enterprise archival data storage

First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML HOUSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin”